Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III pivotal trial of a long-acting intramuscular injection of glatiramer acetate (GA Depot) in patients with primary progressive MS (PPMS)

Next Previous
Trial Profile

Phase III pivotal trial of a long-acting intramuscular injection of glatiramer acetate (GA Depot) in patients with primary progressive MS (PPMS)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 04 Apr 2022 New trial record
  • 31 Mar 2022 According to a Mapi Pharma media release, the company plans to initiate this trial at the end of 2022.
  • 30 Mar 2022 According to a Mapi Pharma media release, based on the initial efficacy and safety results from an ongoing Phase II study in PPMS and the patent protection, the company is seeking a partner to support this Phase III development and co-marketing of GA Depot for PPMS.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top